Drug Profile
Research programme: CCR1 receptor antagonists - Ligand
Alternative Names: PS 031291; PS 375179Latest Information Update: 11 Mar 2011
Price :
$50
*
At a glance
- Originator Pharmacopeia Drug Discovery
- Developer Ligand Pharmaceuticals
- Class Small molecules
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer
- Discontinued Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 11 Mar 2011 Ligand's CCR1 receptor antagonists research programme is still available for licensing. www.ligand.com
- 09 Feb 2009 PS 031291 is available for out-licensing (http://www.pharmacopeia.com)
- 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals